Watson introduces new oral contraceptive, Vestura

Download PDF Copy

Jan 18 2012

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Pharma, Inc. has launched Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz(R) oral contraceptive product. Watson began shipping the product today. Watson's Vestura(TM) is indicated for the prevention of pregnancy and for the treatment of moderate acne in women at least 14 years old only if the patient desires an oral contraceptive for birth control.

Yaz(R) and its generic versions had total U.S. sales of approximately $510 million for the twelve months ending November 30, 2011, according to IMS Health.

Source:

Watson Pharmaceuticals, Inc.

Posted in: Women's Health News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Off-label drug helps one boy with autism speak, parents say. But experts want more data.

Mass General Brigham study shows US obesity could jump from 40% to 70%

Scientists test whether chaya leaves can lower blood sugar in diabetes

Study sheds light on how inadequate sleep in teens can contribute to cycles of violence

How IoT, AI, and mobile technologies are transforming manufacturing and R&D

‘Sick to my stomach’: Trump distorts facts on autism, tylenol, and vaccines, scientists say

Largest study of African American brain tissue reveals key Alzheimer gene activity

Global cancer cases and deaths expected to soar by 2050 despite advances in treatment

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.